uniQure’s (QURE) “Outperform” Rating Reaffirmed at Royal Bank of Canada

uniQure (NASDAQ:QURE)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Royal Bank of Canada in a research report issued on Tuesday,Benzinga reports. They currently have a $24.00 price target on the biotechnology company’s stock. Royal Bank of Canada’s price target points to a potential upside of 56.97% from the stock’s previous close.

Several other research firms have also issued reports on QURE. Wells Fargo & Company upgraded uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. Leerink Partners raised their target price on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of uniQure in a research note on Tuesday, December 10th. Guggenheim reissued a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. Finally, Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and an average price target of $34.38.

uniQure Price Performance

Shares of QURE stock opened at $15.29 on Tuesday. The firm has a market cap of $745.23 million, a price-to-earnings ratio of -3.08 and a beta of 0.41. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a 50-day moving average price of $12.39 and a 200 day moving average price of $8.56.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. Research analysts expect that uniQure will post -3.74 EPS for the current year.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.74% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On uniQure

Several institutional investors have recently bought and sold shares of QURE. RTW Investments LP bought a new position in shares of uniQure during the 3rd quarter worth approximately $49,000. China Universal Asset Management Co. Ltd. grew its position in uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares in the last quarter. Atria Investments Inc acquired a new stake in uniQure in the 3rd quarter valued at $53,000. Quarry LP bought a new stake in uniQure during the 3rd quarter worth about $58,000. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in shares of uniQure by 21.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,306 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.